Solid lipid nanoparticles for pulmonary delivery of insulin

Liu, Jie; Gong, Tao; Fu, Hualin; Wang, Chang-Guang; Wang, Xiuli; Chen, Qian; Zhang, Qin; He, Qin; Zhang, Zhirong

doi:10.1016/j.ijpharm.2008.01.008

Cited by 222 publications

(87 citation statements)

References 56 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…109 Several studies have been published on the pulmonary applications of SLNs as local delivery carriers for small molecules 42 or as systemic delivery carriers for macromolecules. 73,132 Pandey and Khuller 42 studied the chemotherapeutic potential of SLNs incorporating rifampicin, isoniazid and pyrazinamide against experimental tuberculosis, and observed the slow and sustained-release of drugs from the SLNs in vitro and in vivo. Gene delivery Poly(lactide-co-glycolide)…”

Section: Dovepressmentioning

confidence: 99%

Nanomedicine in pulmonary delivery

Mansour¹,

Rhee²,

Wu³

2009

IJN

409

269

View full text Add to dashboard Cite

Section: Dovepressmentioning

confidence: 99%

Nanomedicine in pulmonary delivery

Mansour¹,

Rhee²,

Wu³

2009

IJN

409

269

View full text Add to dashboard Cite

“…Liu et al (83) developed novel nebulizer-compatible solid lipid nanoparticles for pulmonary delivery of insulin by the reverse micelle-double emulsion technique and their finding suggested that SLN could be used as a potential carrier for pulmonary delivery of insulin improving its stability as well as bioavailability.…”

Section: Pulmonary Administrationmentioning

confidence: 99%

Solid lipid based nanocarriers: An overview / Nanonosači na bazi čvrstih lipida: Pregled

Pardeshi¹,

Rajput²,

Belgamwar³

et al. 2012

Acta Pharmaceutica

182

View full text Add to dashboard Cite

In the era of nanoparticulate controlled and site specific drug delivery systems, use of solid lipids to produce first generation lipid nanoparticles, solid lipid nanoparticles (SLN), became a revolutionary approach in the early nineties. The present review is designed to provide an insight into how SLN are finding a niche as promising nanovectors and forms a sound basis to troubleshoot the existing problems associated with traditional systems. Herein, authors had tried to highlight the frontline aspects prominent to SLN. An updated list of lipids, advanced forms of SLN, methods of preparation, characterization parameters, and various routes of administration of SLN are explored in-depth. Stability, toxicity, stealthing, targeting efficiency and other prospectives of SLN are also discussed in detail. The present discussion embodies the potential of SLN, now being looked up by various research groups around the world for their utility in the core areas of pharmaceutical sciences, thereby urging pharmaceutical industries to foster their scale-up.

show abstract

“…The fine particle fraction (FPF) and the alveolar respirable fraction (ARF) were determined using the following equations (Abd-Elbary et al, 2008;Liu et al, 2008;Nasr et al, 2012):…”

Section: Powder X-ray Diffraction (Xrd)mentioning

confidence: 99%

Respirable controlled release polymeric colloid (RCRPC) of bosentan for the management of pulmonary hypertension: in vitro aerosolization, histological examination and in vivo pulmonary absorption

2017

View full text Add to dashboard Cite

Respirable controlled release polymeric colloid (RCRPC) of bosentan for the management of pulmonary hypertension: invitro aerosolization, histological examination and invivo pulmonary absorption, Drug Delivery, 24:1, 188-198, DOI: 10.1080/10717544.2016 AbstractBosentan is an endothelin receptor antagonist (ERA) prescribed for patients with pulmonary arterial hypertension (PAH). The oral delivery of bosentan possesses several drawbacks such as low bioavailability (about 50%), short duration of action, frequent administration, hepatotoxicity and systemic hypotension. The pulmonary administration would circumvent the presystemic metabolism thus improving the bioavailability and avoids the systemic adverse effects of oral bosentan. However, the short duration of action and the frequent administration are the major drawbacks of inhalation therapy. Thus, the aim of this work is to explore the potential of respirable controlled release polymeric colloid (RCRPC) for effective, safe and sustained pulmonary delivery of bosentan. Central composite design was adopted to study the influence of formulation and process variables on nanoparticles properties. The particle size, polydispersity index (PDI), entrapment efficiency (EE) and in vitro bosentan released were selected as dependent variables. The optimized RCRPC showed particle size of 420 nm, PDI of 0.39, EE of 60.5% and sustained release pattern where only 31.0% was released after 16 h. The in vitro nebulization of RCRPC indicated that PLGA nanoparticles could be incorporated into respirable nebulized droplets better than drug solution. Pharmacokinetics and histopathological examination were determined after intratracheal administration of the developed RCRPC to male albino rats compared to the oral bosentan suspension. Results revealed the great improvement of bioavailability (12.71 folds) and sustained vasodilation effect on the pulmonary blood vessels (more than 12 h). Bosentan-loaded RCRPC administered via the pulmonary route may therefore constitute an advance in the management of PAH.

show abstract

Solid lipid nanoparticles for pulmonary delivery of insulin

Cited by 222 publications

References 56 publications

Nanomedicine in pulmonary delivery

Nanomedicine in pulmonary delivery

Solid lipid based nanocarriers: An overview / Nanonosači na bazi čvrstih lipida: Pregled

Respirable controlled release polymeric colloid (RCRPC) of bosentan for the management of pulmonary hypertension: in vitro aerosolization, histological examination and in vivo pulmonary absorption

Contact Info

Product

Resources

About